Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group trial 9401

Journal of Clinical Oncology

Volumn 24, Issue 16, 2006, Pages 2428-2436

  Tanner, Minna ^a   Isola, Jorma ^a   Wiklund, Tom ^a   Erikstein, Björn ^a   Kellokumpu Lehtinen, Pirkko ^a   Malmström, Per ^a   Wilking, Nils ^a   Nilsson, Jonas ^a   Bergh, Jonas ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; THIOTEPA; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; GENE AMPLIFICATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL TRIAL; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RISK; SCANDINAVIA; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; SCANDINAVIA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33744969590     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.9264     Document Type: Article

References (29)

1. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339:974-984, 1998
2. Early Breast Cancer Trialists' Collaborative Group: Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 1:CD000487, 2002
3. Clark GM: Prognostic and predictive factors, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott-Raven Publishers, 1996, pp 461-485
4. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998
5. Sjostrom J, Krajewski S, Franssila K, et al: A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. Br J Cancer 78:812-815, 1998
6. Daidone MG, Veneroni S, Benini E, et al: Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer 84:580-586, 1999
7. Paik S, Bryant J, Park C, et al: ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998
8. Thor AD, Berry DA, Budman DR, et al: ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360, 1998
9. Bitran JD, Samuels B, Trujillo Y, et al: HER2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage III breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 2:1509-1513, 1996
10. Di Leo A, Gancberg D, Larsimont D, et al: HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107-1116, 2002
11. Ross JS, Fletcher JA, Linette GP, et al: The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 8:307-325, 2003
12. Kauraniemi P, Barlund M, Monni O, et al: New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 61:8235-8240, 2001
13. Di Leo A, Isola J: Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: Are we at the end of the beginning? Clin Breast Cancer 4:179-186, 2003
14. Jarvinen TA, Tanner M, Barlund M, et al: Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142-150, 1999
15. Jarvinen TA, Tanner M, Rantanen V, et al: Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to the topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-847, 2000
16. Bergh J, Wiklund T, Erikstein B, et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial - Scandinavian Breast Group 9401 study. Lancet 356:1384-1391, 2000
17. Isola J, Tanner M, Forsyth A, et al: Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 10:4793-4798, 2004
18. Schoenfeld D: Partial residuals for the proportional hazards regression model. Biometrika 689: 239-241, 1982
19. Pegram MD, Finn RS, Arzoo K, et al: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547, 1997
20. Jacobson KK, Morrison LE, Henderson BT, et al: Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer 40: 19-31, 2004
21. Goldhirsch A, Wood W, Gelber R, et al: Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357-3365, 2003
22. Coon JS, Marcus E, Gupta-Burt S, et al: Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8:1061-1067, 2002
23. Park K, Kim J, Lim S, et al: Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39.631-634, 2003
24. Cardoso F, Durbecq V, Larsimont D, et al: Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 24:201-209, 2004
25. Knoop AS, Knudsen H, Balslev E, et al: Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483-7490, 2005
26. Coombes RC, Bliss JM, Wils J, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial - The International Collaborative Cancer Group. J Clin Oncol 14:35-45, 1996
27. Piccart MJ, Di Leo A, Beauduin M, et al: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19:3103-3110, 2001
28. Fumoleau P, Kerbrat P, Romestaing P, et al: Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 21:298-305, 2003
29. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003